Janus Henderson Group
ATYR

Janus Henderson Group’s aTyr Pharma ATYR Stock Holding History

Janus Henderson Group’s Portfolio ATYR Stock Details ATYR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-1,514
Closed -$107K – 1346
2017
Q3 		$107K Buy
1,514
+407
+37% +$18.9K ﹤0.01% 1281
2017
Q2 		$53K Buy
+1,107
New +$51.8K ﹤0.01% 1305

Other funds holding ATYR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
PVMCV
Polaris Venture Management Co V Boston, Massachusetts $14.1M AUM 121.41% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group's ATYR Position: Q4 2017 in Review

Janus Henderson Group sold out of aTyr Pharma (ATYR) in Q4 2017, closing a stake of 1,514 shares — an estimated $107K sold.

Janus Henderson Group first reported a position in ATYR in Q2 2017 and held it in 2 quarters. The position peaked at $107K in Q3 2017. 41 funds tracked by Wall St. Rank hold ATYR as of Q4 2017.

  • Janus Henderson Group reported no remaining aTyr Pharma position as of Q4 2017 after selling out during the quarter.
  • Janus Henderson Group sold 1,514 aTyr Pharma shares in Q4 2017, an estimated $107K.
  • Janus Henderson Group first reported a position in aTyr Pharma in Q2 2017 and held it in 2 quarters.
  • Janus Henderson Group's aTyr Pharma position peaked at $107K in Q3 2017.
  • 41 funds tracked by Wall St. Rank held aTyr Pharma as of Q4 2017.

Based on Janus Henderson Group's 13F filing for Q4 2017, filed 9 Feb 2018.